These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 31010693)
1. An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma. Dudani S; Savard MF; Heng DYC Eur Urol Focus; 2020 Jan; 6(1):34-36. PubMed ID: 31010693 [TBL] [Abstract][Full Text] [Related]
2. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031 [TBL] [Abstract][Full Text] [Related]
3. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844 [TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy for renal cell carcinoma - current status]. Grimm MO; Foller S Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324 [TBL] [Abstract][Full Text] [Related]
5. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146 [TBL] [Abstract][Full Text] [Related]
6. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308 [TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610 [TBL] [Abstract][Full Text] [Related]
8. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035 [TBL] [Abstract][Full Text] [Related]
10. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274 [TBL] [Abstract][Full Text] [Related]
11. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions. Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639 [TBL] [Abstract][Full Text] [Related]
12. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173 [TBL] [Abstract][Full Text] [Related]
14. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423 [TBL] [Abstract][Full Text] [Related]
15. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042 [TBL] [Abstract][Full Text] [Related]